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Leprosy is characterized by chronic infection with Mycobacterium leprae where the progression to disease is strongly dependent upon the host genetic background [1] [2] [3] [4] [5] [6] . One focus of current leprosy control efforts is the prevention of nerve damage 7 . A major contributor to nerve damage are sudden-onset episodes of excessive inflammatory responses termed type-1 reactions (T1R) 8 . Without timely intervention T1R can cause irreversible nerve damage due to a pathological cell-mediated inflammatory response directed against host peripheral nerve cells 9 .
Depending on the epidemiological setting, T1R episodes can afflict 30% to 50% of leprosy cases but are more common among older patients 10 . While approximately one third of T1R are diagnosed at the time of leprosy diagnosis, T1R episodes can occur years after successful completion of therapy presumably in the absence of M. leprae bacilli 10, 11 .
Host genetic predisposition is an important aspect of T1R pathogenesis. A prospective study of host responses to M. leprae antigen identified a gene-set signature that predisposed to T1R 12 . In addition, candidate gene approaches identified six protein coding genes in association with T1R [13] [14] [15] [16] [17] [18] [19] . More recently a genome-wide association study (GWAS) identified a long noncoding RNA in chromosome 10 as T1R risk factor in independent populations and also provided suggestive evidence for the PRKN (formerly PARK2) as T1R susceptibility gene 18 . Here, we tested if nonsynonymous variants with a likely functional impact at the protein level were enriched in the seven coding genes previously associated with T1R. We identified protein altering variants in the PRKN and LRRK2 genes as T1R risk modulating factors. Since PRKN and LRRK2 are established Parkinson's disease (PD) susceptibility genes, we tested if T1R risk variants had been implicated in PD. Indeed, we found T1R risk modulating amino acid changes significantly enriched among PD susceptibility variants. Parkin loss-of-function mutations were shared risk factors for T1R and PD while a gain-of-function amino acid substitution in LRRK2 had an antagonist pleiotropic effect and was protective for T1R and a risk factor for PD.
Results
We selected from our sample of Vietnamese leprosy patients 237 T1R-affected subjects (cases), which we matched by age at leprosy diagnosis, gender and clinical subtype of leprosy with 237 T1R-free subjects as controls for deep re-sequencing of seven T1R susceptibility genes (Table S1, Table S2 ). We focused our analysis on the 63 variants that represented nonsynonymous changes, or insertion/deletions, and tested those for association with T1R. None of the studied subjects were homozygous or compound heterozygotes for nonsynonymous rare variants in any given gene. Of the seven genes, only non-synonymous changes in PRKN and LRRK2 showed significant evidence for association with T1R ( Table 1) .
The LRRK2 R1628P variant is associated with protection from T1R
Nonsynonymous LRRK2 variants were significantly enriched among T1R-free controls ( Figure 1A , Table 1 ). Common variants did not contribute to this effect since restriction of the analysis to variants with MAF < 0.05 did not cause a decay in the strength of LRRK2 association with T1R (Table 1 ). In contrast, the two low-frequency variants P755L and R1628P were highly enriched (>3-fold excess) in T1R-free subjects. When we performed single variant analyses we observed a strong protective effect of the LRRK2 R1628P mutation for T1R (p = 0.004, OR (95% CI) = 0.29 (0.13 -0.67) for 1628P carriers). None of the other variants, including P755L, displayed significant univariate association with T1R (Table S3) . We conditioned the gene-wise association of LRRK2 with T1R on the R1628P mutation and observed a large drop in the strength of association (p SKAT -O = 1.6x10 -4 to p SKAT -O = 0.01). By also adjusting on the P755L variant, LRRK2 association with T1R protection became nominally non-significant (p SKAT -O = 0.06). However, given the remaining trend in favour of association it is possible that additional rare LRRK2 variants contributed to protection from T1R.
To validate the detected LRRK2 -T1R associations we decided to test for a possible impact of the 1628P and 755L mutations on LRRK2 functional activity. Hence, we genomeedited RAW cells to express hetero-and homozygously the 1628P and 755L mutant forms of LRRK2. We also generated a LRRK2 knock-out line as negative control. Mutant and wildtype RAW cells were infected with Mycobacterium bovis (BCG) or M. leprae. Infection with BCG induced LRRK2 expression in all cells, but no significant difference of expression levels was observed between the LRRK2 wildtype and mutant proteins (Figure 2A , B). Following infection with BCG the 1628P mutant form mediated a significantly stronger respiratory burst while production of reactive oxygen species (ROS) by the 755L line was indistinguishable from the response of wildtype cells ( Figure 2C, D) . Compared to wildtype cells, the 1628P mutant also triggered a stronger respiratory burst in response to M. leprae ( Figure 2E ). Interestingly, the response of heterozygous LRRK2 1628 P/R cells was indistinguishable from the one mounted by homozygous 1628 P/P cells suggesting a dominant effect of the mutation ( Figure 2F ).
Since LRRK2 had been linked to protection from apoptosis, we assessed the impact of the 1628P and 755L mutant LRRK2 proteins on BCG-triggered apoptosis. We infected cells expressing LRRK2 wild type, 1628P/P or 755L/L LRRK2 mutant forms, and LRRK2 knock-out cells with BCG for 24 hours. We then determined in BCG infected and uninfected controls the 
Rare nonsynonymous variants in PRKN are T1R-risk factor
For the PRKN gene we observed nine missense variants of which two, rs1801474 (S167N) and rs1801582 (V380L), were common and seven were rare including the novel PRKN mutation K299R ( Figure 1B) . PRKN rare variants were observed only in T1R-affected cases resulting in strong evidence for gene-wise association of PRKN with T1R susceptibility ( Figure   1B ). To evaluate if the PRKN association with T1R was only driven by rare variants we re- were predicted to be damaging in all five databases curated (Table S4) . Two other substitutions (R42C and K299R) were predicted to impair Parkin function in more than one database while the remaining two rare variants located towards the terminal end of Parkin (R396G and K408R) were predicted to be tolerable ( Figure 1B and Table S4 ). In summary, five Parkin rare variants observed in T1R-affected cases have consistent data supporting a functionally detrimental impact at the protein level.
Pleiotropic effect of LRRK2 and PRKN amino acid changes on T1R and Parkinson's disease
Since mutations in LRRK2 and PRKN are main causes of Parkinson's disease we assessed if the amino acid substitutions identified in our study were curated in two PD mutation databases 20, 21 . The main evidence for association between LRRK2 and T1R was provided by variants P755L and R1628P and, while not causally linked with PD, both variants are risk factors for PD (Table 2) . Interestingly, antagonistic pleiotropy of the 1628P variant was also observed for PD and Alzheimer's disease 22 . For the PRKN gene, 5 of the 7 amino acid mutations identified as risk factors for T1R had previously been implicated in PD ( Figure 2 , Table 2 ). Moreover, one of the 7 variants was novel and therefore had not been detected in PD or healthy subjects. This shared co-occurrence of amino acid mutations between PD and T1R was strongly non-random (p = 8.7 x10 -4 ; Table S5 ). When we disregarded the novel variant sharing became more significant (1.5 x10 -4 ). Substitutions at Parkin residues 42 and 275 are frequently observed in subjects suffering from PD. The amino acid substitutions R42C observed in oneT1R-affected individual causes the same salt bridge disruption between UBL and RING1 domains as observed for the most common PD R42P mutation ( Figure 4) . Moreover, the R275Q amino acid substitution affects the interaction between the RING1 and IBR domains of Parkin as observed for the PD R275W mutation (Figure 4 ). Alterations at the other three Parkin mutations shared between PD and T1R (D243N, R366W and R369G) also result in structural variation ( Figure S3 ).
Discussion
Despite the availability of an efficacious treatment for leprosy, the incidence of leprosy has shown only a moderate global decline over the past 15 years 23 . This unexpected epidemiological situation has given rise to two major areas of research. The first theme concerns the identification of the unknown mode of transmission of the M. leprae bacillus. The second theme is focused on the early detection of signs of leprosy and the prevention of nerve damage in leprosy patients 7 .
A main contributor to nerve damage are T1R and the question remains why only a minority of leprosy patients develop T1R and how to identify those who are at risk. While the clinical manifestation of this predisposition requires the trigger by M. leprae it is noteworthy that T1R can occur after microbiological cure of leprosy.
Acute episodes of T1R are characterized by a cytokine storm which is indicative of dysregulated inflammatory responses. Prospective transcriptomic analyses of the immune response to M. leprae antigen and a genome-wide association study support the central role of host genetics in the break-down of coordinated gene regulation in the T1R phenotype 12, 18 .
Additional candidate gene T1R association studies identified T1R susceptibility genes that were investigated in the present manuscript. However, these genetic studies focused on the role of common genetic variants which are more likely to impact on gene expression levels and not on the functional capacity of encoded proteins. Here, we show that for 2 of 7 T1R susceptibility genes, uncommon amino acid mutations that impact protein function are signif icant contributors to T1R risk that act independently of common regulatory variants. Our findings that a gain-offunction mutation in the LRRK2 protein is protective for T1R while loss of function variants in Parkin are T1R risk factors are consistent with the concept that a genetically controlled mis-communication between pro-and anti-inflammatory host responses underlies the T1R phenotype.
Of the seven T1R candidate genes studied (Table S2) ligases show at least some overlap. As for T1R, our findings validated two key players of nerve damage in leprosy and identified E3 ligases as critical players of this pathology. However, the observed antagonistic pleiotropy of LRRK2 variants in T1R and PD highlights the challenges of host directed therapies that may be aimed at these key mediators of nerve damage in leprosy.
One of the unexpected findings was the observation that the 1628P mutation blocked BCG triggered apoptosis but increased the respiratory burst of RAW cells in response to BCG.
These findings are consistent with a previous report that the LRRK2 1628P allele promoted increased kinase activity 24 . ROS generated during a respiratory burst down-regulate inflammation 25 , and systemic ROS does induce apoptosis which is generally considered an antiinflammatory cellular response since apoptotic cells release multiple anti-inflammatory mediators 26 . However, if apoptotic cells are not cleared efficiently, this may lead to increased inflammation 27 . This dual role of apoptosis may underlie the antagonistic pleiotropy of 1628P in PD and T1R. It is possible that the reduction of anti-inflammatory molecules resulting from abrogated apoptosis mediated by the 1628 mutant protein is disease-promoting for PD patients while the resulting lower yield of apoptotic debris in leprosy patients may protect against T1R. A previous prospective study of leprosy patients at risk of T1R identified higher pro-and antiinflammatory gene expression in those patients destined to suffer T1R 12 . This suggested a breakdown in the regulation of the inflammatory response in T1R patients opening the possibility that the 1628P mutation, at least in the periphery, re-establishes the equilibrium between pro-and anti-inflammatory pathways.
Parkin is an evolutionary conserved modulator of innate immunity to infectious agents 28, 29 and genetic variants of PRKN were associated with increased susceptibility to both leprosy and typhoid fever in ethnically diverse populations 2, 30, 31 . However, it was not resolved if the role of Parkin in infectious and neurodegenerative disease reflected the promiscuous nature of E3 ligase functions or was based on shared mechanisms of dysfunctional host immunity. Here, we showed that rare amino acid changes associated with T1R in Parkin are predicted loss of function mutations that display a striking overlap with established risk factors for PD. Indeed, five out of the seven Parkin rare variants associated with T1R susceptibility were substitutions at the same amino acid residue as observed in PD while a sixth novel T1R-risk variant (K299R) was adjacent to the annotated I298L and I298S PD mutations (Table 2) 32, 33 . As the shared Parkin mutations are mainly connected to early-onset PD (EOPD) our findings strongly suggested that EOPD shares a mechanistic overlap with T1R, an inflammatory disorder triggered by M. leprae.
While the same Parkin mutations are implicated in neurodegeneration in the brain and nerve cell destruction in the periphery, the question remains if related infectious triggers are necessary for the manifestation of both disease phenotypes. Parkin, together with PINK1, is critically important for mitochondrial quality control by modulating mitophagy, a form of autophagy which delivers damaged mitochondria to lysosomes for degradation. However, there is a large body of experimental evidence which extends the role of PRKN and PINK1 in mitochondrial quality control beyond the control of mitophagy 34 . Given that mitochondria are key players of adaptive and innate immunity, and the suggested role of Prkn and Pink in autoimmune-mediated neuronal destruction in a mouse model, it is possible that unrecognized infection provides the missing link between impaired mitochondrial quality control and dysregulated neuro-inflammation in EOPD 35 . The genetic link between EOPD and T1R leads to one additional consideration. Since a majority of T1R cases present within 3 years of diagnosis and treatment of leprosy it seems prudent to consider the role of temporally remote and largely resolved infections as possible triggers for some cases of EOPD. Careful screening for the immunological footprint of such remote infections in EOPD cases may provide additional support for a role of infections in EOPD.
Online Methods

Population sample and deep resequencing
A total of 474 leprosy affected subjects were selected from our records of the Vietnamese population. The follow-up for leprosy affected individuals without T1R was greater than 5 years.
An Illumina TrueSeq Custom Amplicon v1.5 was used to create libraries containing the exonic sequences of seven targeted genes. Individual indexed libraries were pooled in batches of 96 samples randomly mixing cases and controls for paired-end sequencing using Illumina MiSeq 600 cycles kit v3. Next, the paired-end sequences were aligned to the reference build hg19 of the human genome using a banded Smith-Waterman algorithm from Illumina. In all steps, standard parameters were used except for the exclusion of duplicated read as our approach was based on 
Alignment and variant calling
Haplotype caller was used to create individual GVCF files that were combined to perform joint genotyping using the GATK pipeline 36 . Variants were hard filtered using the suggested GATK thresholds for amplicon sequencing employing the following parameters for SNPs (QD < 2, MQ < 40, SOR > 3, MQRankSum < -12.5 and ReadPosRankSum < - 
Statistical analyses
The enrichment of protein altering variants per gene was evaluated using two different statistical tests: the variable threshold (VT) 38 method and the optimal unified burden and SNPset Kernel Association Test (SKAT-O) 39 both implemented in the software EPACTS 40 . Briefly, VT is a burden test which collapse rare variants in a gene into a single burden variable and test for the cumulative effect of rare variants in the gene by regressing the burden variable on the phenotype. Burden tests are the most powerful rare variant association tests when most variants are causal and the effects are in the same direction. However, in the presence of a mixed of protective and deleterious variants in a gene, the non-burden SKAT is more powerful. To maximize power under both scenarios, SKAT-O adaptively combines a weighted burden and the SKAT statistics. SKAT-O with default parameters was used to weight variants according to their minor allele frequency adding the optional correction for studies with less than 2000 samples.
Bonferroni was used for multiple testing correction by considering two tests (SKAT-O and VT) in 7 genes and two conditions (transcribed variants and protein altering) resulting in a cut-off of p < 0.002 to be significant at the gene-wise level. To evaluate if the effect per gene was driven by a particular variant, an univariable analysis was performed for nonsynonymous polymorphisms with MAF > 0.01 under additive model in PLINK 41 . For the genes associated with T1R in the gene-wise analysis that also presented a variant with p < 0.1 in the univariate model a conditional gene-wise association analysis was performed with EPACTS.
A hypergeometric test was used to determine if T1R and PD cases shared substitutions at the same amino-acid residues for the LRRK2 and Parkin proteins more often than expected by chance. As not all amino acids of a protein have the same probability of being mutated in the general population, two databases -(i) dbSNP 42 and (ii) gnomAD 43 -were accessed to catalog both LRRK2 and Parkin mutated residuals. In the enrichment analysis, only protein mutated residuals with frequency lower than 1% in the curated databases were considered as baseline since common mutations are likely to be present in both T1R and PD samples merely due to their frequency. For instance, in the curated databases Parkin presented 287 out of its 465 amino acids residuals mutated at least once in the general population. The number of Parkin residues associated with PD in the PDmutDB 20 and LOVD 21 databases was 72. The hypergeometric test calculated the statistical significance of randomly selecting 5 PD-associated residues in the T1R samples when 6 out of the 287 known mutated positions were observed in our population (Table   S5 ). The same test was performed including novel variants for PRKN and applied to the LRRK2 gene.
Genome-editing with CRISPR/Cas9
For the genome-editing of RAW 264.7 cells with CRISPR/Cas9, the gRNAs for generation of LRRK2 P755L, R1628P and KO cell lines were synthesized by using GeneArt precision gRNA synthesis kit from Thermo Fisher according to the manufacturer's instruction (Table S6) . On the day prior to transfection, RAW264.7 cells were split into a new flask with fresh growth medium such that the cells reach 70-90% confluency the following day. On the day of electroporation, cells were washed with PBS and treated with 0.25% trypsin-EDTA for 8-10 min at 37°C. After neutralization of trypsin, 1 x 10 5 cells per transfection were transferred to a 1.5 ml microcentrifuge tube. In parallel with the preparation of cells for electroporation, 2µg
Cas9 protein and 400 ng gRNA were mixed in 10 l of resuspension buffer R and incubated at room temperature for 10 min to form stable Cas9-gRNA complex. Prepared cells were resuspended in the buffer R (provided in Neon transfection system 10 l kit, Thermo Fisher) containing the Cas9-gRNA complex and 50 pmol of donor homology-directed recombination (HDR) templates was added (Table S6 ). The cell mixture was transferred into a 10 l Neon tip with Neon pipette and electroporation was performed using the following parameters: pulse voltage 1680 V, pulse width 20 ms and pulse number 1. After electroporation, cells from two Neon tips were transferred to 12-well plates and cultured on growth media for 4 days. Next, the cells were counted and serially diluted to 2 x 10 4 cells/ml, 5 x 10 2 cells/ml and 5 cells/ml. A volume of 200 µl of 5 cells/ml suspension was dispensed to each well of 96-well plates. Plates were incubated at 37°C in a 5% CO2. Genomic DNA was isolated from single clone colonies.
The donor target region of single clones was Sanger sequenced to check incorporation of the designed variants. Selected RAW264.7 cells were maintained in Dulbecco's Modified Eagle (DMEM) medium supplemented with 10% fetal bovine serum and 1% streptomycin-penicillin, and incubated in a humidified atmosphere containing 5% CO2 at 37°C. The cells were passaged every 3 days.
Growth of mycobacteria
BCG Russia cultures were maintained in middlebrook 7H9 medium supplemented with 10% ADC, 0.1% Tween 80, and 0.2% glycerol at 37°C on a roller. On the day of infection to break up large aggregates into single cells, re-suspended BCG was sonicated in a water bath for 20 s x 5 times, followed by passing the BCG through a 22 1/2-G needle 8 times. Bacterial load was determined by plating serial 10-fold dilutions of BCG and CFUs were estimated from colony counts after at least 3 weeks of incubation. The Thai-53 isolate M. leprae was harvested from both hind foot pads of athymic nude mice (Envigo, USA) inoculated 5-7 months previously with 3 x 10 7 bacilli. The harvested bacilli were enumerated by direct count according to Shepard's method and held overnight at 4 -8 o C pending quality control testing for contamination and viability. Viability of the M. leprae suspension was measured by determining the rate of 14C-palmitic acid oxidation to 14CO2 by radiorespirometry as described previously 44 . A 24hr count of at least 6000cpm was considered viable. Freshly harvested bacilli were always employed in experiments within 24-48hrs of harvest.
Western Blot analysis
Total cellular lysates were resolved on a 4 to 12% Tris-Glycine gel (Bio-Rad) and electrophoretically transferred to polyvinylidene difluoride membranes (Bio-Rad). The membranes were blocked with 5% BSA in TBS-T (Tris-buffered saline-0.1% Tween 20) for 1 h at room temperature, a procedure followed by incubation with primary antibodies overnight at 4C. A rabbit monoclonal antibody against LRRK2 (Abcam) was used at 1:1,000 dilution. A mouse anti-GAPDH monoclonal antibody (Thermo Fisher) was used at a 1:10,000 dilution.
Upon extensive washing, the membrane was developed with enhanced chemiluminescence detection reagents (Bio-Rad), followed by imaging using a ChemiDoc Touch imaging system (Bio-Rad). Experiments were performed in triplicates.
Reactive oxygen species (ROS) detection
Different cell lines were seeded in 96-well plates at a concentration of 3x10 4 oxidative stress detection reagent /10 ml of 1X wash buffer) was added prior to incubation of plates in a humidified incubator (37°C, 5% CO2) for 30 min. Readings were acquired at wavelengths 488/520nm on a plate reader. Each experiment was performed at least three times, each in triplicate.
FACS analysis of apoptosis
One the day prior to infection, RAW264.7 cells expressing LRRK2 wildtype or mutant protein or depleted for LRRK2 gene expression by knock-out were separately cultured at a concentration of 6 x10 5 /well in a 6-well plate for 16-18 hrs. The cells were then infected with or without BCG (MOI 10:1) for 24 hours followed by apoptosis analysis using Annexin V-APC and Zombie Aqua TM fixable viability dye as detailed in the Biolegend manual. Briefly, cells were washed twice with cold PBS and incubated with 1ml of 5 mM EDTA/PBS on ice for 30 minutes 
Database curation
The predicted impact at the protein level for nonsynonymous variants described in our study was assessed in five databases as in previous studies 45, 46 . The algorithms used for the predictions were PolyPhen2 HumDiv and HumVar 47 , SIFT 48 , LRT 49 , Mutation Taster 50 and CADD 51 . To evaluate if rare variants associated with T1R were also reported in PD cases, we used the PDmutDB (http://www.molgen.vib-ua.be/PDMutDB/) 20 and the Leiden Open Variation Database (LOVD) for Parkinson's Disease (http://grenada.lumc.nl/LOVD2/TPI/home.php) 21 . To evaluate the frequency of the mutations of the targeted genes we used the dbSNP v147 (https://www.ncbi.nlm.nih.gov/snp) 42 and gnomAD (http://gnomad.broadinstitute.org/) 43 databases.
Spatial modeling of Parkin mutations
To visualize the spatial localization of mutations we used a crystallography model of the inactive Parkin (PDB:5C1Z) 52 . The structural impact of amino acid substitutions in Parkin was predicted with PyMol 53 . Briefly, rearrangements in Parkin conformation were estimated for amino acids in a five Armstrong (Å) radius from the most likely rotamer of the mutated residuals. The impact in polarity and hydrogen bounding was also assessed for amino acids surrounding the mutated site. One amino acid was mutated at a time with the reference allele observed in the crystallography kept for all other positions. The impact of mutations in Parkin residues 357 to 360, 383 to 390 and 406 to 413 could not be assessed, including the mutation at position 408 identified in our study. WT, cells expressing the LRRK2 1628 P/P variant consistently showed increased ROS production following exposure to both BCG and M. leprae (C, E). Compared to LRRK2 WT, cells heterozygotic for LRRK2 1628 R/P also displayed higher ROS production upon M. leprae stimulation which was not significantly different from the response of homozygous LRRK2 1628 P/P carriers. Table S4 . Annotation of protein altering variants identified in the T1R targeted genes.
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Parkin mutated residues observed in Parkinson's disease cases were extracted from the PDmutDB and LOVD database. Mutations in Parkin residues were accounted only once even if different amino acid substitutions were cataloged for a given position. Substitutions in Parkin residues 167 and 380 were not included in the analyses due to their high frequency in the general population. A hypergeometric test was used to investigate the pleiotropic enrichment. *If the novel variant observed in a T1R case by our study was to be included as "No PD" variant the pleiotropic effect would still remain highly significant (p = 8.7
x10 -4 ). Table S6 . Oligonucleotides used in the CRISPR/Cas9 constructs. 
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